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Chronic hepatitis B virus (HBV) infection poses a serious public health problem in many parts of the world.
Presently, even with proper joint immunoprophylaxis, approximately 10-15% of newborns from HBV carrier mothers
suffer from HBV infection through intrauterine transmission. One of the risk factors is the level of maternal viraemia.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV. A few studies have evaluated
the efficacy of telbivudine in preventing intrauterine HBV infection during late pregnancy. So we conducted this
meta-analysis to arrive at an evidence-based conclusion. We searched Medline/PubMed, EMBASE, Cochrane Library,
Web of Knowledge and China Biological Medicine Database from January 1990 to December 2011. Relative risks
(RR) of the seropositivity rates for hepatitis B surface antigen (HBsAg) and HBV DNA in newborns and infants were
studied. Mean differences (MD) in maternal HBV DNA levels were reviewed. Finally two randomised controlled trials
(RCTs) and four non-randomised controlled trials (NRCTs) were left for analysis which included 576 mothers in total,
of whom 306 received telbivudine treatment and 270 did not receive any drug. All newborns received hepatitis B
vaccine (HBVac) and hepatitis B immunoglobulin (HBIG) after birth. The seropositivity rate for HBsAg or HBV DNA
was significantly lower in the telbivudine group, both at birth and at 6–12 months follow up. Meanwhile, maternal
HBV DNA levels prior to delivery were significantly lower in the telbivudine group. In addition, the frequency of
serum creatine kinase (CK) elevation was similar in the two groups. Our meta-analysis provides preliminary evidence
that telbivudine application in late pregnancy is effective in the interruption of intrauterine HBV infection, with no
significant adverse effects or complications. More high quality, well-designed, double-blinded, randomised
controlled and large size clinical trials are needed for further investigation and more convincing results in the
future.
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Chronic hepatitis B virus (HBV) infection poses a ser-
ious public health problem in many parts of the world,
especially in developing countries [1]. In the Asia-Pacific
region, vertical transmission of HBV is a key factor in its
endemicity. The risk of chronic hepatitis B (CHB) virus
infection is inversely proportional to the age at which
the infection was acquired [2], and at least 50% of cases
acquired the infection during either the perinatal period* Correspondence: hzruanbing@gmail.com
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reproduction in any medium, provided the oror in early childhood [3], including through vertical
transmission.
Presently, the World Health Organization, the World
Gastroenterology Organisation and the Ministry of
Health of China recommend joint immunoprophylaxis
with the hepatitis B vaccine (HBVac) and hepatitis B im-
munoglobulin (HBIG) to prevent HBV mother-to-child
transmission (MTCT). However, even with proper joint
immunoprophylaxis, approximately 10-15% of newborns
from HBV carrier mothers suffer from HBV infection
through intrauterine transmission [4,5]. Risk factors for
HBV immunoprophylaxis failure include maternal hepa-
titis B e antigen (HBeAg) positivity and increased hepa-
titis B surface antigen (HBsAg) titre and HBV DNAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been reported to increase the possibility of intrauterine
HBV infection [7]. Hence, antiviral therapy plus immu-
noprophylaxis administered to HBV carrier mothers dur-
ing pregnancy has been suggested to effectively prevent
MTCT by reducing maternal HBV DNA levels and
developing passive immunisation in the newborns. The
oral nucleoside analogue lamivudine is believed to pre-
vent the HBV intrauterine transmission during the last
months of pregnancy [8-10]. Many studies have also
shown reliable prevention effects of this drug [8,11,12].
Telbivudine, classified as Food and Drug Administra-
tion (FDA) pregnancy risk category B [2,3], is a syn-
thetic thymidine nucleoside analogue with activity
against HBV. It was reported that telbivudine treatment
produced rapid reduction in serum HBV DNA levels in
a 4-week dose-escalation trial and a 1-year trial con-
ducted with Asian and Western CHB patients [13]. Be-
sides, global and Chinese clinical trials have indicated
that telbivudine provides greater antiviral and clinical
efficacy than lamivudine in patients with HBeAg-
positive and HBeAg-negative CHB [13,14].
A few studies have evaluated the efficacy of telbivudine
in preventing intrauterine HBV infection during late
pregnancy. We performed this meta-analysis to arrive at
an evidence-based conclusion. We also investigated the
safety of telbivudine during pregnancy.
Methods
Search strategy
Medline/PubMed, EMBASE, Cochrane Library, Web of
Knowledge and China Biological Medicine Database
were searched for relevant randomised controlled trials
(RCTs) aimed at preventing MTCT of HBV by compar-
ing telbivudine with placebo or no treatment (control).
Query results included articles published between Janu-
ary 1990 and December 2011 in English or Chinese
peer-reviewed publications (including abstracts). Because
published studies were limited, we expanded the search
to include non-randomised controlled trials (NRCTs).
We also hand-searched bibliographies of reviews, ori-
ginal studies and relevant conference articles, and con-
tacted some investigators directly. The search was
designed using the key words “telbivudine or Tyzeka or
Sebivo”, “HBV or hepatitis B virus” and “intrauterine or
maternity or mother or pregnancy or pregnant”.
Inclusion and exclusion criteria
Inclusion criteria included the following: (1) maternal
blood was positive for HBsAg and HBV DNA; and (2)
the diagnoses of intrauterine HBV infection and MTCT
were clear; and (3) mothers were HBV carriers or
patients with compensated hepatitis [15]. Studies were
excluded if they were reviews, meta-analysis or casereports (with no control group). Because HBIG or other
antiviral drugs may reduce serum HBV DNA levels, we
also excluded studies in which these were used before
labour [16]. All newborns (in both the treatment and
control groups) received HBIG and HBVac after birth.
Outcome measures
The primary outcomes were the rates of newborn HBV
infection at birth and 6–12 months follow up. Secondary
outcomes included maternal blood HBV DNA levels be-
fore treatment and prior to delivery, adverse events on
the mother (such as elevations in creatine kinase (CK)
and aminotransferase (ALT), postpartum haemorrha-
ging, complications in pregnancy and during delivery),
and adverse effects on newborn parameters (such as
weight, height and 1-minute Apgar score).
Study quality
Two investigators (Min Deng and Xin Zhou) independ-
ently assessed study quality. All RCTs were graded using
the Jadad criteria [17]. These criteria include the three
methodological features of randomisation, blinding and
accountability. NRCTs had to meet the cases matched
by the patient’s characteristics. All studies had defined
inclusion and exclusion criteria for patients. Disagree-
ments were resolved by consensus when necessary.
Data extraction
Extracted data included patient characteristics, design
and methods of the study, inclusion and exclusion cri-
teria, treatment duration and dose, primary and second-
ary outcomes, complications, and adverse events.
Statistical analysis
Data analysis was carried out with the use of Review
Manager Software 5.0 (Cochrane Collaboration). The
meta-analysis was performed using the Mantel-Haenszel
fixed-effects or random-effects models, depending on
the absence or presence of significant heterogeneity [18].
Statistical heterogeneity was assessed by the chi-square
(Chi2) test and I-squared (I2) test and was considered to
exist when I2 > 50%. We used the relative risk (RR) of
the main dichotomous outcomes as the measure of effi-
cacy, which are shown in a forest plot. The 95% confi-
dence interval (CI) for the pooled RR was also provided.
Continuous outcomes were presented as a mean differ-
ence (MD) because HBV DNA levels of the studies were
reported in the same scale (log10 copies/ml measured by
the Polymerase Chain Reaction). Subgroup analysis was
conducted to compare the effects in different study types
(RCT or NRCT). A funnel plot estimating the precision
of trials was examined to evaluate the potential for selec-
tion bias. The overall effect of intervention achieved
statistical significance if P < 0.05. Because we used only
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mittee was not required.
Results
Characteristics of the studies
We identified 1,712 citations through our searches, from
which six studies involving 576 mothers (306 of whom
were treated with telbivudine) were selected [5,19-23]. A
map of the literature search and selection process is
shown in Figure 1. Of the studies included, five were
published in Chinese [19-23] and one was published in
English as original articles [5]. Two studies were RCTs
[19,22], but they did not describe the method of ran-
domisation in detail and received Jadad scores of 2. Two
studies were not included in our meta-analysis because
of the use of telbivudine in combination with HBIG be-
fore labour [24,25]. In the trial by Han et al. [5], one
mother in the telbivudine group had twins, and 10
mothers and their infants (4 in the telbivudine group
and 6 in the control group) dropped out at 7 months
postpartum. The characteristics of the six included stud-
ies are shown in Table 1.
Newborn and infant HBsAg seropositivity
Five studies (1 RCT and 4 NRCTs) demonstrated new-
born HBsAg seropositivity at birth [5,19-21,23]. The
newborn HBsAg positive rates were 8.7% (24/277) in the
telbivudine group and 27.1% (65/240) in the controlFigure 1 Map of the literature search and selection process.group. Based on the Chi2 and I2 analyses [Chi2 = 0.28,
df = 4 (P = 0.99); I2 = 0%], a fixed-effects approach
was used to summary estimate the relative risk of telbivu-
dine versus control. The pooled data demonstrated that
newborn HBsAg seropositivity was higher in the control
group than in the telbivudine group [RR = 0.31, 95% CI
(0.20, 0.49), P < 0.00001]. We further conducted meta-
analysis based on study type (RCT or NRCT) to minimise
the potential heterogeneity. However, regarding this par-
ameter, only one RCT [19] could be included. Thus, we
pooled the data from the four NRCTs [5,20,21,23]. We
found that newborn HBsAg seropositivity was lower in the
telbivudine group than in the control group [RR = 0.31,
95% CI (0.20, 0.49), P < 0.00001] (Figure 2). The results
were consistent.
At age 6–12 months, the infant HBsAg positive rates
were 0.7% (2/281) in the telbivudine group and 12.2%
(29/238) in the control group (2 RCTs and 3 NRCTs)
[5,19,21-23]. Based on the Chi2 and I2 analyses, signifi-
cant differences in heterogeneity were not observed be-
tween the two groups [Chi2 = 1.41, df = 4 (P = 0.84);
I2 = 0%]. A summary estimate of the relative risk of tel-
bivudine versus control showed a significant difference
[RR = 0.11, 95% CI (0.04, 0.31), P < 0.0001]. We also
conducted meta-analysis for two RCTs [19,22] and
three NRCTs [5,21,23]. The pooled RR of the two RCTs
was 0.20 [95% CI (0.04, 1.10)]. Although it did not
achieve statistical significance (P = 0.06), there was a
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Figure 2 Forest plots of telbivudine vs. control on newborn HBsAg seropositivity. A. Pooled effect from the combination of RCTs and
NRCTs. B. Pooled effect from NRCTs.
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infants in the telbivudine group. The pooled results of
the three NRCTs showed that the RR was 0.08 [95% CI
(0.02, 0.32), P = 0.0004] (Figure 3).
We further explored the selection biases, and found
no significant asymmetry of the funnel plots (Figure 4).Figure 3 Forest plots of telbivudine vs. control on infant HBsAg seropThe immunoprophylaxis outcomes for newborns and
infants are shown in Table 2.
Newborn and infant HBV DNA seropositivity
Only three NRCTs examined in this meta-analysis
reported HBV DNA seropositivity at birth [5,20,21]. Theositivity at age 6–12 months.
Figure 4 (See legend on next page.)
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Figure 4 Funnel plot analysis to detect selection bias. A. Funnel plots of studies on newborn HBsAg seropositivity. B. Funnel plots of studies
on infant HBsAg seropositivity. C. Funnel plots of studies on newborn HBV DNA seropositivity. D. Funnel plots of studies on infant HBV DNA
seropositivity. E. Funnel plots of studies on maternal blood HBV DNA levels before treatment. F. Funnel plots of studies on maternal blood HBV
DNA levels prior to delivery. G. Funnel plots of studies on elevation of maternal serum creatine kinase.
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the telbivudine group and 17.2% (31/180) in the control
group. Using the Chi2 and I2 analyses, heterogeneity was
assessed and not found to be significant [Chi2 = 2.14,
df = 2 (P = 0.34); I2 = 6%]. The pooled data of the three
studies showed a significant difference between the two
groups [RR = 0.18, 95% CI (0.08, 0.40), P < 0.0001]
(Figure 5).
At age 6–12 months, three trials (1 RCT and 2 RCTs)
demonstrated infant HBV DNA seropositivity [5,21,22].
The infant HBV DNA positive rates were 0.9% (2/222)
in the telbivudine group and 14.6% (26/178) in the con-
trol group. According to Chi2 and I2 analyses, significant
differences in heterogeneity were not observed [Chi2 =
0.34, df = 2 (P = 0.84); I2 = 0%]. A summary estimate of
the relative risk of telbivudine versus control using a
fixed-effects approach demonstrated that there was a
significant difference in infant HBV DNA seropositivity
between two groups [RR = 0.09, 95% CI (0.02, 0.30), P =
0.0001]. As only one RCT [22] could be included in this
meta-analysis, we pooled the data from the two NRCTs
[5,21]. We found that the results were consistent [RR =
0.07, 95% CI (0.01, 0.36), P = 0.001] (Figure 6).
We further explored the selection biases of the out-
comes, and found no significant asymmetry of the funnel
plots (Figure 4).Maternal blood HBV DNA levels
Five studies (1 RCT and 4 NRCTs) described maternal
blood HBV DNA levels before telbivudine treatment in
detail [5,19-21,23]. Heterogeneity was assessed and not
found to be significant [Chi2 = 3.52, df = 4 (P = 0.48);
I2 = 0%]. A summary estimate of the MD of telbivudine
versus control using a fixed-effects approach demon-
strated that maternal blood HBV DNA levels were simi-
lar before telbivudine treatment [MD = 0.09, 95% CI
(−0.04, 0.22), P = 0.16]. As we had to exclude one RCT
[19], we conducted a meta-analysis for the four NRCTs
[5,20,21,23]. The pooled data also showed no significant
difference in maternal blood HBV DNA levels before
treatment [MD = 0.12, 95% CI (−0.02, 0.26), P = 0.08]
(Figure 7).
Also among the five studies, Chi2 and I2 analyses identi-
fied significant heterogeneity in maternal blood HBV
DNA levels between two groups prior to delivery [Tau2 =
1.35, Chi2 = 97.90, df = 4 (P < 0.00001); I2 = 96%]. A sum-
mary estimate of the MD of telbivudine versus controlusing a random-effects approach demonstrated that the
maternal blood HBV DNA level was lower in the telbivu-
dine group prior to delivery [MD = −4.06, 95% CI (−5.13,
-2.98), P < 0.00001]. We also further performed a meta-
analysis among the four NRCTs, and the results were con-
sistent [MD = −4.27, 95% CI (−5.43, -3.11), P < 0.00001]
(Figure 8).
In addition, we explored the selection biases, and found
no significant asymmetry of the funnel plots (Figure 4).
Safety
Elevation of serum CK in newborns (8 in the telbivudine
group and 9 in the control group) was the only adverse
event reported by Zhang et al. [19]. Thirteen mothers
presented with elevated CK levels in another study by
Zhang et al. [21]. The only reported adverse event in
Yao’s trial [23] was elevated CK levels in 3 mothers in
the telbivudine group and 2 mothers in the control
group. In addition, 5 mothers in Zeng’s study [20] and
88 mothers in Han’s study [5] had light elevation in
serum ALT levels after drug withdrawal. At 7 month fol-
low up, pneumonia and other adverse events in infants
were evaluated and considered not to be drug related in
Han’s study.
Fives studies (2 RCTs and 3 NRCTs) examined in
this meta-analysis reported serum CK levels in
mothers [19-23]. According to Chi2 and I2 analyses
[Tau2 = 3.74, Chi2 = 3.66, df = 1 (P = 0.06); I2 = 73%], a
random-effects approach was used to summary estimate
the relative risk of telbivudine versus control. The
pooled data demonstrated that the frequency of serum
CK elevation was similar in the two groups [RR = 5.53,
95% CI (0.24, 124.94), P = 0.28] (Figure 9). Because two
studies substantially contributed to the overall effect of
the meta-analysis, we did not divide the studies into sub-
groups to investigate heterogeneity.
We further explored the selection bias, and found no
significant asymmetry of the funnel plots (Figure 4).
Discussion
Of the estimated 350 million individuals chronically
infected with HBV worldwide, it is generally accepted
that at least 50% of cases acquired their infections dur-
ing either the perinatal period or in early childhood,
especially in areas of high endemicity. In China, where
the prevalence of HBV is high, 85-90% of transmis-
sions can be prevented successfully with proper
Table 2 The immunoprophylaxis outcomes for newborns and infants
Study Newborns number HBsAgseropositivity n (%) HBV DNA seropositivity n (%)
Telbivudine/
Control
Telbivudine/ Control Telbivudine Control
n At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mo 12 mo At birth 6 mo 7 mp 12 mo
Zhang 2009
[21]
31/30 2 (6.5%) NA 0 (0%) NA 5 (16.7%) NA 4 (13.3%) NA NA NA NA NA NA NA NA NA
Zhao 2010
[22]
30/30 NA NA NA 1 (3.3%) NA NA NA 3 (10.0%) NA NA NA 1 (3.3%) NA NA NA 8 (26.7%)
Zeng 2010
[20]
22/26 2 (9.1%) NA NA NA 9 (34.6%) NA NA NA 0 (0%) NA NA NA 4 (15.4%) NA NA NA
Zhang 2010
[21]
60/60 6 (10.0%) NA NA 1 (1.7%) 18 (30.0%) NA NA 11 (18.3%) 5 (18.3%) NA NA 1 (1.7%) 18 (30.0%) NA NA 11 (18.3%)
Yao 2011
[23]
28/30 1 (3.6%) 0 (0%) NA NA 5 (16.7%) 4 (13.3%) NA NA NA NA NA NA NA NA NA NA
Han 2011
[5]
136/94 13 (9.6%) NA 0 (0%) NA 28 (29.8%) NA 7 (8.0%) NA 0 (0%) NA 0 (0%) NA 9 (9.6%) NA 7 (8.0%) NA















Figure 5 Forest plots of telbivudine vs. control on newborn HBV DNA seropositivity.
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http://www.virologyj.com/content/9/1/185immunoprophylaxis [5]. However, approximately 10-
15% of newborns from HBV carrier mothers suffer from
HBV infection because of intrauterine transmission.
MTCT, which includes intrauterine transmission, peri-
natal transmission and transmission during lactation, is
an important reason for failure of immune prophylaxis
[26,27]. It has been demonstrated that active immunisa-
tion (HBVac) combined with passive immunisation
(HBIG) can effectively prevent perinatal transmission
and transmission during lactation [26,28,29]. None-
theless, the incidence of intrauterine HBV infection
remains as high as 43% when maternal serum HBV
DNA exceeds 108 copies/ml [30], even with prompt ad-
ministration of active and passive vaccination. del
Canho et al. also reported that intrauterine infection
occurs only when maternal serum HBV DNA levels are
high (> 150 pg/ml or 3.16 × 107 copies/ml) [31]. Intra-
uterine HBV transmission occurs primarily during the
third trimester [32] and is presumed to cause a minority
of the infections not prevented by prompt immunisa-
tion. Probable reasons for transmission are thought toFigure 6 Forest plots of telbivudine vs. control on infant HBV DNA se
combination of RCTs and NRCTs. B. Pooled effect from NRCTs.be the breach of the placental barrier caused by HBV
[3] and polymorphisms in some cytokine genes (such as
those encoding for interferon-γ and tumour necrosis
factor-α) [33].
In general, it is not recommend to initiate antiviral
therapy with nucleoside analogues in HBV-infected
persons who are immune tolerant. However, they have
the same risk of intrauterine infection as CHB patients
for their high HBV DNA levels. Because the risk of
HBV intrauterine infection is clearly related to the
level of maternal viraemia, and most foetal organs have
developed by the third trimester, a strategy to interrupt
this process is maternal treatment with antiviral drug
in late pregnancy. Interferon and peg-interferon are
contraindicated during pregnancy largely because of
their known anti-proliferative effects. Lamivudine, the
first nucleoside analogue inhibitor to be approved for
the treatment of CHB, has long been used for both
HIV and HBV infection during pregnancy and has dis-
played reliable prevention effects [34]. Even though
lamivudine is classified as FDA pregnancy risk categoryropositivity at age 6–12 months. A. Pooled effect from the
Figure 7 Forest plots of telbivudine vs. control on maternal blood HBV DNA levels before treatment. A. Pooled effect from the
combination of RCTs and NRCTs. B. Pooled effect from NRCTs.
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http://www.virologyj.com/content/9/1/185C, the European Association for the study of the Liver
also confirmed its safety during late pregnancy in 2009
[35]. However, it was also reported that reducing mater-
nal HBV DNA levels even to undetectable status by
lamivudine in late pregnancy could not guarantee pre-
vention of intrauterine HBV infection in the newborns
[36]. Telbivudine was approved by the FDA in 2006
and the State Food and Drug Administration in 2007
for the treatment of patients with CHB, and has
demonstrated faster and better efficacy than lamivudineFigure 8 Forest plots of telbivudine vs. control on maternal blood HB
combination of RCTs and NRCTs. B. Pooled effect from NRCTs.in patients with HBeAg-positive and HBeAg-negative
CHB disease.
A few studies have evaluated the efficacy of telbivudine
application in preventing intrauterine HBV infection
during late pregnancy. Therefore we conducted this
meta-analysis to arrive at an evidence-based conclusion.
In this meta-analysis, the treatment group consisted of
306 mothers who received 600 mg/d telbivudine from
the second or third trimester of pregnancy until delivery
or 1 month after delivery. The control group consistedV DNA levels prior to delivery. A. Pooled effect from the
Figure 9 Forest plots of telbivudine vs. control on elevation of maternal serum creatine kinase.
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All newborns received HBIG and HBVac after birth. The
pooled results clearly showed that the seropositivity rate
for HBsAg or HBV DNA was significantly lower in the
telbivudine group, both at birth and at 6–12 months fol-
low up. Meanwhile, maternal HBV DNA levels prior to
delivery were significantly lower in the telbivudine
group. We further conducted meta-analysis based on
study type (RCT or NRCT) to minimise any potential
heterogeneity and found that the type of study design
did not affect the conclusion. However, we should pay
more attention to the evidence grades of these included
trials. Because published studies were limited, only six
trials were included in the meta-analysis. Two trials con-
tained randomised controls, but the details of the ran-
domisation sequence were not provided. The other four
trials included non-randomised controls. In the Han [5],
Zeng [20] and Zhang, 2010 [21] studies, the mothers
self-selected themselves into one arm or the other.
When some demographic features were presented, more
of the control group had abnormal ALT levels [5]. In
Yao’s study [23], the mothers were divided into different
groups according to baseline ALT levels. Thus, more
high-quality, well-designed and randomised controlled
multi-centre trails are necessary to verify the results in
the future.
As an orally bioavailable L-nucleoside analogue with
potent activity against HBV, telbivudine has shown no
effects on human nucleotides and DNA synthesis [37].
Toxicology research has also demonstrated that telbivu-
dine has no significant organ toxicity, carcinogenicity,
genotoxicity, mitochondrial toxicity in vitro, teratogen-
icity, or embryo-foetal toxicity [13,38]. In the phase III
GLOBE trial, most adverse events reported were classi-
fied as mild or moderate in severity and were not attrib-
uted to telbivudine, and elevations in serum CK were
more common in the telbivudine group. Based on its
characteristics, telbivudine is listed by the FDA as a
pregnancy category B drug. The treatment guidelines of
the Asian Pacific Association for the Study of the Liveralso designated telbivudine as a replacement antiviral
therapy during pregnancy in 2008 [39]. In our meta-
analysis we analysed elevations in serum CK, elevated
ALT levels after drug withdrawal and other adverse
events. Since the reported studies only evaluated the
short-term effects of telbivudine and only a few studies
reported adverse events, the long-term safety of telbivu-
dine in infants still need to be assessed in the future. In
addition, we found that the number of infected infants
at age 6–12 months was less than the number of
infected newborns. The probable reason for this decline
is that maternal blood containing HBsAg and HBV
DNA was introduced into the bodies of the newborns
through the umbilical cord during delivery, which were
later neutralised by anti-HBs of HBIG [40].
To our knowledge, this is the first systematic meta-
analysis of this topic. We are convinced that our search
strategy was comprehensive and exhaustive. We comply
with the standardized guidelines on the reporting of sys-
tematic reviews according to the PRISMA statement and
the PRISMA checklist (see Additional file 1). Two inves-
tigators (Min Deng and Xin Zhou) independently
extracted data and entered them in a customised form.
Disagreements were resolved by consensus when neces-
sary. However, the following limitations of our meta-
analysis should be considered. First, we searched for
studies published only in English or Chinese. Second,
due to limited published studies, we expanded the search
to include NRCTs. Third, only a few studies were
included and they had small sample sizes. For these rea-
sons, we could not perform a deep analysis. Besides, all
included studies were performed in mainland China.
Therefore, more clinical studies performed in different
populations and other regions are necessary to access
the generalisability of the results.
Conclusions
Our meta-analysis provides preliminary evidence that
telbivudine application in late pregnancy is effective in
the interruption of intrauterine HBV infection, with no
Deng et al. Virology Journal 2012, 9:185 Page 12 of 13
http://www.virologyj.com/content/9/1/185significant adverse effects or complications. More high
quality, well-designed, double-blinded, randomised con-
trolled and large size clinical trials are needed for further
investigation and more convincing results in the future.
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